More than 15 years ago, the first generation of genetically engineered mouse (GEM) models of prostate cancer was introduced.
These transgenic models utilized prostate-specific promoters to express SV40 oncogenes specifically in prostate epithelium. Since the description of these initial models, there have been a plethora of GEM models of prostate cancer representing various perturbations of oncogenes or tumor suppressors, either alone or in combination. This review describes these GEM models, focusing on their relevance for human prostate cancer and highlighting their strengths and limitations, as well as opportunities for the future.
Written by:
Irshad S, Abate-Shen C. Are you the author?
Herbert Irving Comprehensive Cancer Center, Departments of Urology and Pathology & Cell Biology, Columbia University College of Physicians and Surgeons, New York, NY, USA.
Reference: Cancer Metastasis Rev. 2012 Nov 1. Epub ahead of print.
doi: 10.1007/s10555-012-9409-1
PubMed Abstract
PMID: 23114843
UroToday.com Investigative Urology Section
